clinical trial · NCT07172022
A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)
Hoffmann-La Roche·phase2·withdrawn
Antiphospholipid SyndromeCrovalimabPlaceboVKA
brief summary
The main purpose of this study is to evaluate the efficacy of crovalimab compared with placebo as an add-on therapy to vitamin K antagonist (VKA) in participants with APS.
started
Mar 16, 2026
primary completion
Mar 11, 2030
completion
Dec 2, 2030
last updated
Mar 2, 2026
official title
A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating Efficacy, Safety, and Pharmacokinetics of Crovalimab in Patients With Antiphospholipid Syndrome (APS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol